

TABLE 1. Demographics and clinical characteristics of patients undergoing allo-HSCT

Patient	Number
Patients	92
First HSCT / $\geq 2$ HSCT	78 / 14
Sex (M / F)	54 / 38
Age (years)	10.3 (median 0.4 – 28.1)
Disease	
Hematological malignancy	63
Solid tumor	14
Immunodeficiency	2
Aplastic anemia	10
Metabolic disorders	3
Stem cell source	
BM	36
PBSC	5
CB	51
BM related	26 (23 sibling, 3 parent)
BM unrelated	10
PB related	4 (4 sibling)
PB unrelated	1
HLA matching (antigen)	matched 39 / mismatched 53
Conditioning	MAC 45 / RIC 47
GVHD prophylaxis	
CsA + MTX	20
FK506 + MTX	12
CsA + mPSL	54
Others	6
Post-HSCT complications	
Infection	
Bacteremia	11
Fungal infection	13
Acute GVHD Grade II - IV	38
Grade III - IV	35
Chronic GVHD	30

Abbreviations: HSCT, hematopoietic stem cell transplantation; M, male; F, female; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; HLA, human leukocyte antigen; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; HD, high-dose; GVHD, graft-versus-host disease; CsA, cyclosporin; FK506, tacrolimus; MTX, methotrexate; mPSL, methylprednisolone; CMV, cytomegalovirus